ft 20 sep 93 intern compani news second threat glaxo zantac glaxo victori friday novopharm canadian manufactur gener drug us patent zantac world best sell medicin increas british group chanc win second patent case next year genpharm canadian gener compani smaller novopharm due challeng glaxo patent next may lawyer repres genpharm attend novopharm case heard north carolina near glaxo us headquart canadian group claim unstabl liquid form drug glaxo patent expir decemb 1995 insuffici differ market form justifi differ patent stabl form patent expir 2002 novopharm would abl market gener version zantac us januari 1996 glaxo victori crucial compani futur last financi year zantac ulcer treatment gener sale pound 2 17bn equival 44 per cent group turnov sale drug whose us patent recent expir halv year half zantac sale us analyst believ case depress share 100p share close 644p friday glaxo full year result earlier month dr richard syke chief execut warn addit threat zantac patent challeng remain expiri next year us patent zantac main competitor smithklin beecham tagamet zantac compet cheap gener version drug erad helicobact pylori bacterium recent discov implic ulcer doctor decid erad bug rather prescrib zantac type drug market could collaps counter non prescript version best sell anti ulcer drug tagamet merck pepcid immediaci threat reced last week refus us food drug administr advisori committe recommend otc version tagamet new gener drug astra losec gener version unstabl liquid form zantac patent expir end 1995 dr syke play threat argu doubt qualiti gener manufactur